Phase II, Placebo-Controlled, Double-Blind Study of the Selegiline Transdermal System (STS) in the Treatment of HIV-Associated Cognitive Impairment.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Selegiline (Primary)
- Indications Cognition disorders; Dementia
- Focus Adverse reactions; Therapeutic Use
- 21 May 2012 Biomarkers information updated
- 18 May 2012 Additional lead trial investigators added as reported by ClinicalTrials.gov.(Parent trial: NCT00013585)
- 18 May 2012 Additional lead trial investigators added as reported by ClinicalTrials.gov.(Parent trial: NCT00013585)